StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research note published on Tuesday morning. The brokerage issued a hold rating on the stock.
TherapeuticsMD Price Performance
Shares of NASDAQ:TXMD opened at $1.04 on Tuesday. TherapeuticsMD has a 12 month low of $0.70 and a 12 month high of $2.75. The company’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.54.
Institutional Investors Weigh In On TherapeuticsMD
An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.
Featured Articles
- Five stocks we like better than TherapeuticsMD
- Investing in the High PE Growth Stocks
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Stock Sentiment Analysis: How it Works
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Investing in Construction Stocks
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.